Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

15.1K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
15.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of sella turcica bridging with class II malocclusion: a cephalometric study.

BMC oral health·2026
Same author

CD64 enables TCR-dependent, MHC-independent CTL cytotoxicity of AML cells.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Blood·2026
Same author

Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II.

Leukemia·2026
Same author

CLC-Pred Synergy: Web Application for Predicting Pairwise Drug Combinations with Synergistic Activity Against NCI60 Cancer Cell Lines.

International journal of molecular sciences·2026
Same author

Anti-apoptotic BCL-2 family proteins: from regulatory networks to therapeutic targeting.

Oncogenesis·2026

Related Experiment Video

Updated: Sep 20, 2025

An Automated Differential Nuclear Staining Assay for Accurate Determination of Mitocan Cytotoxicity
07:58

An Automated Differential Nuclear Staining Assay for Accurate Determination of Mitocan Cytotoxicity

Published on: May 12, 2020

7.0K

Novel mitochondria-targeting compounds selectively kill human leukemia cells.

Svetlana B Panina1, Jingqi Pei1, Natalia Baran2

  • 1Department of BioSciences, Rice University, Houston, TX, USA.

Leukemia
|June 7, 2022
PubMed
Summary

New mitochondria-targeting compounds show selective killing of acute myeloid leukemia (AML) cells. These compounds reduce energy production and trigger cell death, offering potential for combination therapies against AML and other blood cancers.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.3K
Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

15.1K

Related Experiment Videos

Last Updated: Sep 20, 2025

An Automated Differential Nuclear Staining Assay for Accurate Determination of Mitocan Cytotoxicity
07:58

An Automated Differential Nuclear Staining Assay for Accurate Determination of Mitocan Cytotoxicity

Published on: May 12, 2020

7.0K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.3K
Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

15.1K

Area of Science:

  • Hematology
  • Mitochondrial Biology
  • Cancer Pharmacology

Background:

  • Acute myeloid leukemia (AML) is characterized by aggressive progression, treatment resistance, and relapse.
  • Mitochondrial dysfunction is a key feature in AML pathogenesis and progression.
  • Targeting metabolic vulnerabilities in cancer cells presents a promising therapeutic strategy.

Purpose of the Study:

  • To identify and characterize novel mitochondria-targeting compounds with selective cytotoxicity against AML cells.
  • To elucidate the mechanism of action of these compounds, focusing on mitochondrial function and cell death pathways.
  • To evaluate the therapeutic potential of these compounds in preclinical models of AML and other hematologic malignancies.

Main Methods:

  • High-throughput screening of mitochondria-affecting compounds (PS compounds) for selective AML cell cytotoxicity.
  • Structure-activity relationship (SAR) studies to optimize compound efficacy and selectivity.
  • Assessment of cellular respiration (ATP production, oxygen consumption) and reactive oxygen species (ROS) generation.
  • Induction of various cell death pathways (ferroptosis, necroptosis, apoptosis) in AML cell lines and primary samples.
  • Combination studies with existing anti-leukemia agents and in vivo efficacy evaluation in a xenograft mouse model.

Main Results:

  • Six PS compounds demonstrated selective cytotoxicity against AML cells in vitro, with significant differences in LD50 compared to healthy cells.
  • Hit compounds impaired ATP production and selectively reduced basal and ATP-linked oxygen consumption in leukemic cells.
  • Compounds derived from PS127 upregulated ROS production and induced ferroptotic, necroptotic, and/or apoptotic cell death in AML models.
  • Synergistic effects were observed when combining these compounds with established anti-leukemia drugs against AML, ALL, and CML.
  • Pilot in vivo studies showed anti-leukemic efficacy, including extended survival in a xenograft model.

Conclusions:

  • Mitochondria-targeting compounds exhibit potent and selective anti-leukemic activity.
  • These compounds disrupt energy metabolism and induce multiple cell death mechanisms in AML cells.
  • The identified compounds show promise as leads for developing novel combinatorial therapies for hematologic malignancies.